CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 161 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2023. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $16 | -97.0% | 491 | -95.9% | 0.00% | -100.0% |
| Q4 2022 | $539 | -99.8% | 12,102 | +35.7% | 0.00% | – |
| Q3 2022 | $250,000 | -43.9% | 8,916 | -46.1% | 0.00% | – |
| Q2 2022 | $446,000 | +7.0% | 16,546 | +35.0% | 0.00% | – |
| Q1 2022 | $417,000 | -16.8% | 12,252 | -5.7% | 0.00% | -100.0% |
| Q4 2021 | $501,000 | -60.6% | 12,990 | -64.8% | 0.00% | 0.0% |
| Q3 2021 | $1,270,000 | +2.4% | 36,911 | -0.5% | 0.00% | 0.0% |
| Q2 2021 | $1,240,000 | +2284.6% | 37,111 | +1357.6% | 0.00% | – |
| Q1 2021 | $52,000 | -89.5% | 2,546 | -91.0% | 0.00% | -100.0% |
| Q4 2020 | $493,000 | +94.9% | 28,144 | +65.0% | 0.00% | – |
| Q3 2020 | $253,000 | -68.9% | 17,062 | -72.7% | 0.00% | -100.0% |
| Q2 2020 | $813,000 | +2610.0% | 62,592 | +356.7% | 0.00% | – |
| Q4 2019 | $30,000 | +275.0% | 13,705 | +227.6% | 0.00% | – |
| Q3 2019 | $8,000 | -46.7% | 4,183 | -27.4% | 0.00% | – |
| Q2 2019 | $15,000 | +275.0% | 5,765 | +596.3% | 0.00% | – |
| Q1 2019 | $4,000 | – | 828 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |